Rainbow Genomics Launches Rapid Whole Genome Sequencing Test for Newborns with Complex Clinical Symptoms

The one-week turnaround time coupled with rapid clinical interpretation helps diagnose critically-ill newborns.

HONG KONG and SAN FRANCISCO

March 9, 2020

Hong Kong-based Rainbow Genomics launches a trio whole genome sequencing test for critically-ill newborns and children with complex clinical symptoms. The test is designed to “rapidly” determine genetic etiologies associated with multiple clinical presentations where traditional testing failed to provide a diagnosis.

Trio whole genome sequencing of the affected child and both parents, is processed at a U.S. CAP-accredited and CLIA-certified laboratory. Simultaneous clinical interpretation is provided by Rainbow’s teams of medical and clinical genetics experts in Hong Kong, U.S. and Japan. Clinical report is issued by a board-certified and licensed medical director in Japan. The turnaround time for this test is approximately one week.

In addition to genome-wide analysis of genetic variants associated with reported symptoms, a list of 1600 genes associated with over 1000 childhood-onset disorders will be further analyzed to assure comprehensiveness of the clinical interpretation. Copy number and structural variation, duplication, exon-wide insertion and deletion variants, as well as small indels and single nucleotide variants are analyzed.

“Genetic disorder is a leading cause of death for newborns and young children. Frequently, the symptoms presented by these patients are complex, and masked by non-causative clinical histories such as prematurity, birth trauma, and sepsis. Traditional-sequential testing often fails to determine the causes of the symptoms, further contributes to the urgency of a timely diagnosis and treatment,” Said Daniel Siu, CEO of Rainbow Genomics. “Trio whole genome sequencing provides the industry-best approach to rapidly determine one or more genetic causes of the underlying disorders found in these critically-ill children”

About Rainbow Genomics
Rainbow Genomics is committed to providing clinically-validated and affordable genetic tests to patients in
Hong Kong, Japan, Singapore and other Asian countries. The company delivers clinical interpretations
specifically for Asians, based on expert understanding of their genetics, and medical care experience in Hong
Kong, Japan, and the United States. Rainbow Genomics specializes in providing whole genome & whole exome sequencing,
pharmacogenomic, hereditary cancer and polygenic risk assessment tests to enable physicians to use genomic information for diagnosis, treatment, and disease prevention. Visit us at rainbowgenomics.com.